SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease.

Autor: Clément AN; Université Côte d'Azur, Inria Sophia Antipolis, Epione Research Project, Sophia-Antipolis, France. Electronic address: clement.abi-nader@inria.fr., Ribaldi F; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, Hospitals and University of Geneva, Geneva, Switzerland., Frisoni GB; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, Hospitals and University of Geneva, Geneva, Switzerland., Garibotto V; Faculty of Medicine, Geneva University, Geneva, Switzerland; Nuclear Medicine, Geneva University, Geneva, Switzerland., Robert P; Université Côte d'Azur, CoBTeK lab, MNC3 Program, Nice, France., Ayache N; Université Côte d'Azur, Inria Sophia Antipolis, Epione Research Project, Sophia-Antipolis, France., Lorenzi M; Université Côte d'Azur, Inria Sophia Antipolis, Epione Research Project, Sophia-Antipolis, France.
Jazyk: angličtina
Zdroj: Neurobiology of aging [Neurobiol Aging] 2022 May; Vol. 113, pp. 73-83. Date of Electronic Publication: 2022 Feb 23.
DOI: 10.1016/j.neurobiolaging.2021.12.015
Abstrakt: SimulAD is a computational disease progression model (DPM) originally developed on the ADNI database to simulate the evolution of clinical and imaging markers characteristic of AD, and to quantify the disease severity (DS) of a subject. In this work, we assessed the validity of this estimated DS, as well as the generalization of the DPM., by applying SimulAD on a new cohort from the Geneva Memory Center (GMC). The differences between the estimated DS of healthy, mild cognitive impairment and AD dementia groups were statistically significant (p-values < 0.05; d ≥ 0.8). DS correlated with MMSE (ρ = -0.55), hippocampal atrophy (ρ = -0.62), glucose hypometabolism (ρ = -0.67), amyloid burden (ρ = 0.31) and tau deposition (ρ = 0.62) (p-values < 0.01). Based on the dynamics estimated on the ADNI cohort, we simulated a DPM for the subjects of the GMC cohort. The difference between the temporal evolution of similar biomarkers simulated on the ADNI and GMC cohorts remained below 10%. This study illustrates the robustness and good generalization of SimulAD, highlighting its potential for clinical and pharmaceutical studies.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: